Mendez-Clemente A, Bravo-Cuellar A, Gonzalez-Ochoa S, Santiago-Mercado M, et al. Dual STAT3 and IL6R inhibition with stattic and tocilizumab decreases migration, invasion and proliferation of prostate cancer cells by targeting the IL6/IL6R/STAT3 axis. Oncol Rep 2022;48.
PMID: 35703345